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Background: Moderately increased albuminuria (MIA) is strongly associated with hyper-
tension (HTN) in patients with type 2 diabetic mellitus (T2DM). However, the association
between risk factors and coexisting HTN and MIA remains unassessed.
Objectives: This study aimed to determine both cross-sectional and longitudinal associa-
tions of risk factors with HTN and MIA comorbidity in patients with T2DM.
Methods: A total of 1,600 patients with T2DM were examined at baseline and longitudinal
data were obtained from 1,337 T2DM patients with at least 2 follow-up visits to assess the
presence of HTN alone (yes/no), MIA alone (yes/no) and the coexistence of both (yes/no) in
a 9-year open cohort study between 2004 and 2013. Bivariate mixed-effects logistic regres-
sion with a Bayesian approach was employed to evaluate associations of risk factors with
HTN and MIA comorbidity in the longitudinal assessment.
Results: After adjustment for age and BMI, patients with uncontrolled plasma glucose, as a
combined index of the glucose proﬁle, were more likely to have HTN [odds ratio (OR): 1.73
with 95% Bayesian credible intervals (BCI) 1.29–2.20] and MIA [OR: 1.34 (95% BCI 1.13–
1.62)]. The risks of having HTN and MIA were increased by a one-year raise in diabetes
duration [with 0.89 (95% BCI 0.84–0.96) and 0.81 (95% BCI 0.73–0.92) ORs, respectively]
and a one-unit increase in non-high-density lipoprotein-cholesterol (Non-HDL-C) [with 1.30
(95% BCI 1.23–1.34) and 1.24 (95% BCI 1.14–1.33) ORs, respectively].
Conclusions: T2DM patients with HTN, MIA, and the coexistence of both had uncontrolled
plasma glucose, signiﬁcantly higher Non-HDL-C, and shorter diabetes duration than the
other T2DM patients. Duration of diabetes and uncontrolled plasma glucose index showed
the stronger effects on HTN and MIA comorbidity than on each condition separately.
Keywords: hypertension, moderately increased albuminuria, microalbuminuria, type 2
diabetes, comorbidity, risk factor
Introduction
Globally, the prevalence of type 2 diabetes mellitus (T2DM) continues to increase.1,2
More than 50% of patients with diabetes mellitus have also hypertension (HTN)3
with three times higher rate than the general population.4 The risk of cardiovascular
disease (CVD) in the T2DM patients with HTN is four-times higher than the
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normotensive non-diabetic people.5 Abnormal levels of
urinary albumin, a marker of kidney disease, occur in 30–
40% of patients with T2DM, and increase the mortality rate
caused by CVD worldwide.6 Furthermore, hypertensive
patients with albuminuria have almost a four-fold increased
risk of ischemic heart disease than hypertensive patients
without albuminuria.7 The association of HTN with moder-
ately increased albuminuria (formerly called microalbumi-
nuria) has been reported frequently.8,9 However, there are
limited numbers of cross-sectional studies, which evaluated
the association of HTN with moderately increased albumi-
nuria (MIA) in patients with T2DM.10 Although the risk
factors associated with only HTN or only MIA in patients
with T2DM have been reported previously,11,12 the associa-
tion of risk factors with MIA and HTN comorbidity com-
bined have yet to be determined.
The main objective of the present study was to identify
and compare the risk factors associated with HTN, MIA,
and the coexistence of both in patients with T2DM using
the mixed-effects models. These approaches incorporate
repeated HTN, MIA, and the coexistence of both preva-
lence data across visits which involve the same T2DM
patients.
Methods
Setting and data collection
This study was focused on high-risk individuals with
T2DM to identify the cross-sectional and longitudinal
associations of risk factors with HTN and MIA comorbid-
ity combined. Furthermore, within the longitudinal assess-
ment, the repeated measurements of potential risk factors
are considered as time-dependent covariates and repeated
measurement of outcome variables took into account the
participants’ changes during the follow-up period.
The present study was conducted with data from the
Isfahan Diabetes Open Cohort Study (IDOCS), an open
cohort study in central Iran to determine various potential
risk factors for CVD in the patients with T2DM. Details of
the design and setting of the IDOCS have been described
elsewhere.11,12 In the IDOCS study, the participants were
followed-up for detection of major CVD events, including
myocardial infarction, unstable angina pectoris, stroke,
and sudden cardiac death.
Study participants
The present study was performed as a sub-study of
IDOCS. Therefore, we retrieved information of 1608
T2DM patients without any history of major CVD
recorded in the database of the Isfahan Endocrine and
Metabolism Research Center (IEMRC), between 2004
and 2013. Physical examination and laboratory measure-
ments were conducted at baseline, and repeated for cases
without any major CVD events. All participants received
follow-up tests, according to the Standard of Medical Care
in Diabetes, to update information on anthropometric and
demographic characteristics, and to record diagnosed MIA
and HTN.12,13 Otherwise, the tests were repeated annually.
According to the inclusion criteria (Figure 1), T2DM
patients with severely increased albuminuria (formerly
called macroalbuminuria) or kidney transplantation14
were excluded at baseline (8 out of 1,608 of patients).
Albumin excertion (24 hrs urine albumin concentrations)
above 300 mg was considered as severely increased albu-
minuria based on the guideline of the European Society of
Cardiology.15
Deﬁnition and assessment of outcomes,
determinants, and confounders
The blood pressurewas taken twice on the right arm of patients
in a seated position, after 15 and 20 mins of rest, using a
standard mercury sphygmomanometer (ALPK2, Japan). The
mean of twomeasurements was recorded as the blood pressure
value. The hypertensive cases were identiﬁed according to the
European Society of Cardiology and European Society of
Hypertension criteria.16 Patients were deﬁned as hypertensive
if they were already being treated with antihypertensive or had
the systolic blood pressure ≥140mmHg, and/or diastolic blood
pressure ≥90mmHg. The blood pressure values were coded as
a binary variable by one in hypertensive patients and zero in
normotensive patients.
In order to measure urinary albumin level accurately,
patients were trained to collect urine samples. Urine sam-
ples with speciﬁc gravity of more than 1.015 were exam-
ined for MIAwhen there was no evidence of infection and/
or hematuria in urinalysis. Urinary albumin and creatinine
were measured by the kits, obtained from the Pars
Azmoon Company, using BT3000, Zinsser Analytic,
Germany. Urinary creatinine was measured by the Jaffe
method to assure that 24 hrs urine was collected correctly.
The European Society of Cardiology criteria was used to
diagnose MIA, and deﬁned by a 24-hrs urine albumin con-
centration between 30 mg and 300 mg.15 In cases that albu-
min concentration exceeded 30 mg, a second 24-hrs urine
sample was collected and examined for MIA. Therefore, we
Hadi Alijanvand et al Dovepress
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coded urinary albumin level as a binary response variable by
one, in patients withMIA, and zero in patients with normoal-
buminuria (24 hrs urine albumin concentrations of <30 mg).
Information on anthropometric indices, duration of
diabetes, blood pressure, lipid proﬁle, and plasma glucose
were collected at baseline and through follow-up intervals.
All clinical examination and laboratory measurements at
baseline and at follow-up visits were performed, using the
same standardized protocol. Anthropometric assessment,
including weight and height, were conducted while parti-
cipants were barefoot and lightly clothed. Patients’ weight
was measured to the nearest 0.1 kg, using the Seca scale
(Hamburg, Germany). Height was measured while patients
were in a standing position with their shoulders in the
normal position, using the Seca stadiometer. The BMI
(kg/m2) was calculated as the weight (kg) divided by
height (m) squared. Duration of diabetes was obtained by
the interval between the age of the patient and their age in
which the diabetes was diagnosed.
Blood samples were taken after 12 hrs overnight fast-
ing to measure biochemical characteristics. FPG was ana-
lyzed by the glucose oxidase method (Clinical Chemistry
Analyzer Liasys, Roma, Italy). HbA1c was measured,
using a DSS machine and the ion-exchange chromatogra-
phy method. Total cholesterol and HDL-C were measured.
LDL-C and Non-HDL-C were calculated by the
Friedewald’s equation17 and subtracting HDL-C from the
total-cholesterol, respectively. All biochemical character-
istics were measured in the central laboratory of the
Isfahan Endocrine and Metabolism Research Center
using the enzyme-linked method.
Statistical analysis
Results were reported as mean (SE) for the quantitative
continuous variables and percentages for the categorical
variables. At baseline, the mean age and BMI of four
groups were compared, including patients with neither
HTN nor MIA as control group, with only MIA, with
T2DM patients without any history of major CVD
Events within the framework of the IDOCS
(N=1608)
Excluded patients with severely increased
albuminuria or kidney transplantation
at baseline
(N=8)Subjects at baseline assessment
(N=1600)
Patients were attended at follow-up
Data from T2DM patients were finally analyzed
based on longitudinal data analysis with model-based
handling missing covariates and dropout data
(N=1337,with 5431 available data during follow-up)
Excluded patients with major CVD events
(N=9)
Excluded patients due to severe increase of
albuminuria during the follow-up
(N=28)
Excluded patients due to co-occurrence of
severely increased albuminuria and
hypertension during follow-up
(N=7)
Patients dropped out  during follow-up
(N=275)
(N=1337) Detect missing data in the covariates, with
missingness rate of 8.6% for glucose
 index and missingness rate of 10.8% for
Non-HDL cholesterol measure
Subject  who were excluded from the
 longitudinal assessment because they did 
not attend any follow-up examinations
(N=263)
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Figure 1 Flow diagram of inclusion data in the presented study.
Abbreviations: T2DM patients, type 2 diabetic mellitus patients; CVD, cardiovascular disease; IDOCS, Isfahan Diabetes Open Cohort Study; HDL, high-density lipoprotein.
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only HTN, and with the coexistence of both, using one-
way analysis of variance (ANOVA) and Tukey’s post-hoc
test. The age- and BMI-adjusted means of the selected
baseline characteristics including diabetes duration, glu-
cose, and lipid proﬁle were calculated and compared
between four groups, based on one-way ANCOVA and
Bonferroni correction post-hoc test. The numbers of
patients with HTN, MIA, and the coexistence of both
were changing during 9 years of follow-up; therefore, we
presented the prevalence of these conditions, annually in
Table 1, and used the mean of prevalence (overall preva-
lence) over the duration of the study.
In the longitudinal assessment, double univariate bin-
ary logit components were obtained from separate logistic
regressions for blood pressure variable alone (dichoto-
mized into “HTN” versus “normotension”) and urinary
albumin level variable alone (dichotomized into “MIA”
versus “normoalbumin”). We used the bivariate longitudi-
nal logistic model to consider the inherent association
between two above-mentioned binary outcomes. The drop-
outs (unbalanced longitudinal data) are shown in Figure 2.
In order to determine the longitudinal associations
between predictors and outcomes, considering the dropout
data, mixed-effects logistic regression was performed as
an appropriate method with enough precision.18 In addi-
tion to dropouts, there was missing data in the covariates
(described in Figure 1). We use all the available follow-up
data (Figure 2) in the open cohort database to maximize
the power and generalizability of the longitudinal results.
We adopted the Bayesian approach, as an advanced statis-
tical approach to estimate parameters while of the missing
covariates handled in the above-mentioned models. The
Bayesian data analysis was conducted, using Open BUGS
version 3.2.3.19 The results of the applied models were
demonstrated as odds ratios (ORs) and related 95%
Bayesian credible intervals (BCI). Deviance information
criterion (DIC) was used to select the best model; a lower
value of DIC, indicating better model ﬁtness. Based on all
available data and the literature, the potential confounders
were also identiﬁed; the confounders were then selected
based on the signiﬁcant correlation (or association) of the
potential confounding variables with both the outcomes
and the risk factors of interest.
We realized that there is a statistically signiﬁcant correla-
tion between lipid and glucose proﬁle using Pearson’s coefﬁ-
cient with P<0.01 (Table S1). Therefore, to deal with the
multicollinearity and to include somehow all lipid and glucose
proﬁles in the ﬁtted longitudinal models, Non-HDL-C was Ta
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presented as lipid proﬁle. Non-HDL-C includes various frac-
tions of lipoproteins: low-density lipoprotein, intermediate-
density lipoprotein, and very low-density lipoprotein. We
also proposed the uncontrolled plasma glucose index as a
combined index of the glucose proﬁle that was coded as a
binary variable. According to the glycemic control recommen-
dation in non-pregnant diabetic patients,20 we created a local
deﬁnition for the uncontrolled plasma glucose index; the FPG
of ≥7.2mmol/L (130mg/dL) and/or 2 hrs PPG of ≥10mmol/L
(180 mg/dL) and/or HbA1C of ≥7% were coded 1 and 0
otherwise. On the other hand, age and BMI were signiﬁcantly
correlated with gender, uncontrolled plasma glucose, diabetes
duration, Non-HDL-C, and the outcomes with (P<0.001).
Therefore, in our implemented longitudinal models, gender
and time-dependent variables including diabetes duration,
uncontrolled plasma glucose index, and non-HDL-C were
considered as the determinants, and age and BMI were
counted as the confounders. Age andBMI adjusted-odds ratios
were presented to determine the association of the gender,
diabetes duration, uncontrolled plasma glucose index, and
increasing Non-HDL-C with the adjusted-odds of having
HTN and MIA, during follow-up visits.
The bivariate logistic regression with random subject-
effects of longitudinal binary responses as blood pressure
and urinary albumin level variables is provided (Equation (1)
and Equation (2)). Where i =1, 2, …, 1,337 is the number of
subject, t=1,2,3, …, 9 is the time point of subject i and
βk1; βk2; k ¼ 0; . . . ; 6 are ﬁxed-effect terms; ui1; ui2 pre-
sent subject-speciﬁc random intercepts for i-th subject.
Blood pressureð Þit jxit; ui1,bern π1itð Þ
Albuminð Þit jxit; ui2,bern π2itð Þ

1
ui1; ui2ð Þ,BN 0;ð Þ
where
logit π1itð Þ ¼ β10 þ Genderitβ11 þ Ageitβ12 þ BMIitβ13
þDiabetes durationitβ14 þ Glucose indexitβ15
þNonHDLCholitβ16 þ u1i
logit π2itð Þ ¼ β20 þ Genderitβ21 þ Ageitβ22 þ BMIitβ23
þDiabetes durationitβ24 þ Glucose indexitβ25
þNonHDLCholitβ26 þ u2i
8>>>><
>>>>:
2
A model which uses HbA1C instead of the uncontrolled
plasma glucose index was further examined to assess
whether the association of glucose proﬁle (based on the
HbA1C as the gold standard of glycemic control), lipid
proﬁle, and diabetes duration with having HTN and MIA
was appropriate. Finally, the above-mentioned model that
Number of patients and visits
263 of T2DM patients who were visited once 263 of T2DM patients without follow-up duration
170 of T2DM patients with 1-year follow-up duration
263 of T2DM patients with 2-year follow-up duration
175 of T2DM patients with 3-year follow-up duration
191 of T2DM patients with 4-year follow-up duration
229 of T2DM patients with 5-year follow-up duration
253 of T2DM patients with 6-year follow-up duration
56 of T2DM patients with 6-year follow-up duration
221 of T2DM patients who were visited twice
13
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e 
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itu
di
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ss
es
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en
t
311 of T2DM patients who were visited three times
304 of T2DM patients who were visited four times
251 of T2DM patients who were visited five times
172 of T2DM patients who were visited six times
71 of T2DM patients who were visited seven times
7 of T2DM patients who were visited eight times
1600 of T2DM who entered into the study 100% 5431
560.4%
4.4%
10.8%
15.7%
19.0%
19.4%
13.8%
16.4% 0
442
933
1216
1255
1032
497
Follow-up durationPercentage
13.1%
14.3%
17.1%
0.4%
16.4%
4.4%
10.8%
15.7%
19.4%
13.8%
19.0%
18.9%
4.2% 12.7%
Follow-up durationNumber of visits
1
2
3
4
5
6
7
1
2
3
4
5
6
7
8
19.7%
Available data in longitudinal
assessment
Figure 2 Description of participants’ number of visits and follow-up durations of type 2 diabetic patients during the follow-up period in the open cohort study.
Abbreviations: T2DM patients, type 2 diabetic mellitus patients.
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included uncontrolled plasma glucose index was selected
based on the model’s selection criteria.
A p-value of <0.05 was considered statistically signiﬁ-
cant for all tests, which were two-tailed. The 95%
Bayesian credible intervals do not include the one value
for considering signiﬁcant effects of risk factors in the
univariate and bivariate Bayesian models.
Results
Results of the descriptive analysis
The mean of prevalence over subsequent years of the open
cohort study (overall baseline prevalence) for HTN, MIA,
and the coexistence of both in patients with T2DM is
10.3% (95% conﬁdence interval [CI] 8.8–11.8), 34.4%
(95% CI 32.7–36.7), and 21.7% (95% CI 19.6–23.7),
respectively (Table 1). Overall, the prevalence of HTN
alone is lower than the prevalence of MIA and the pre-
valence of MIA and HTN combined. Moreover, Table 1
indicates that the prevalence of MIA and HTN decreases
over time.
Results of the cross-sectional assessment
No statistically signiﬁcant difference is observed in most base-
line characteristics between attendees at the follow-up visits
and non-attendees including systolic blood pressure, diastolic
blood pressure, 24 hrs urine albumin concentrations, age,
diabetes duration, height, weight, body mass index (BMI),
glycosylated hemoglobin (HbA1c) level, fasting plasma glu-
cose (FPG), 2 hrs postprandial plasma glucose (PPG) levels,
triglyceride, total cholesterol, low-density lipoprotein-choles-
terol (LDL-C), high-density lipoprotein-cholesterol (HDL-C),
and non-high-density lipoprotein-cholesterol (Non-HDL-C)
concentrations (Table S2).
The baseline characteristics of the normotensive nor-
moalbuminuric T2DM patients and T2DM patients with
HTN, MIA, and the coexistence of both are shown in
Table 2. The gender was balanced between the groups.
However, signiﬁcant differences were observed in mean
age, age-adjusted means of BMI, age- and BMI-adjusted
means of FPG, HbA1C, 2 hrs PPG, total-cholesterol, LDL-
C, Non-HDL-C, across different study groups. According
to the post-hoc comparisons of Bonferroni-corrected test,
adjusted by the baseline age and BMI, the age- and BMI-
adjusted mean differences of glucose and lipid proﬁle are
statistically signiﬁcant between the group of patients with
the MIA and HTN comorbidity, and the group with neither
MIA nor HTN (P<0.001, Table S3 and Figure S1).
Among 1,600 participants at the baseline (1,071 men
and 529 women), 263 subjects were also excluded from
longitudinal assessment because they did not attend the
follow-up examination. Therefore, 1,337 patients (912
men and 425 women) with a mean (standard error [SE])
baseline age of 45.0 (0.24) years old (range 30–81 years
old) who participated in repeated measurements with
available information on outcomes and covariates were
included in the longitudinal assessments. Patients were
followed up until detecting major CVD events (n=9),
severely increased albuminuria (n=35), dropping out
(n=275), or reaching the end of the study (see Figure 1),
all of whom had at least one subsequent review, during the
follow-up duration (median of 4 years and a range of 1–7
years). The detailed description of the participants’ num-
bers of visits and follow-up duration of visits are presented
in Figure 2 for T2DM patients.
Results of the longitudinal analysis
The results of the selected univariate and bivariate long-
itudinal models (Figure 3 and Table S4) determine the
association of the risk factors with MIA and HTN comor-
bidity (for bivariate strategy), in comparison with the long-
itudinal association of the risk factors with MIA, and HTN
disorders separately (for univariate strategies) during fol-
low-ups. In the bivariate model, a joint signiﬁcant positive
association between HTN and MIA was estimated to be
0.47 (95% CI: 0.36–0.57) during the follow-up period. The
bivariate model ﬁts better to the collected data than the
separate analysis of each outcome variable, resulted in a
smaller DIC (Table S4). The associations of potential risk
factors with HTN and MIA in the T2DM patients were
determined after measurement and adjustment for age and
BMI. The results of the un-selected univariate and bivari-
ate longitudinal models, which include Hba1c instead of
glucose index, are also presented in Table S5.
The results of the selected models indicated that the odds
of HTN, MIA, and the coexistence of both were signiﬁcantly
higher in the patients with uncontrolled plasma glucose,
higher Non-HDL-C, and shorter diabetes duration than the
normotensive and normoalbuminuric T2DM patients, after
age- and BMI-adjustment. Furthermore, female patients are
more likely to have MIA alone and MIA with HTN comor-
bidity than male patients (Table S4 and Figure 3).
During follow-up, diabetes duration (age- and BMI-
adjusted ORs [95% BCIs] of HTN: 0.95 [0.91, 0.98] and
MIA: 0.87 [0.80, 0.96] in univariate model versus age- and
BMI-adjusted ORs [95% BCIs] of HTN: 0.89 [0.84–0.96]
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and MIA: 0.81 [0.73–0.92] in bivariate model) showed con-
siderably stronger effects on HTN and MIA in bivariate
model than in univariate model (P<0.05). Uncontrolled
plasma glucose index (age- and BMI-adjusted ORs [95%
BCIs] of HTN: 1.62 [1.23, 1.86] and MIA:1.25 [1.02,
1.56]: in univariate model versus age- and BMI-adjusted
ORs [95% BCIs] of HTN: 1.73 [1.29–2.20] and MIA: 1.34
[1.13–1.62] in bivariate model) shows signiﬁcant stronger
effects on coexisting hypertension and moderately increased
albuminuria than on each condition separately in Table S4
and Figure 3 (P<0.05).
Discussion
The current study demonstrated a high baseline prevalence of
MIA and its coexistence with HTN, among Iranian patients
with T2DM; the prevalence of HTN and MIA comorbidity
was much higher than the prevalence of HTN alone in the
baseline assessment. A large number of T2DMpatients are at
high risk for ischemic heart disease due to HTN and MIA
comorbidity.7 Moreover, decreasing trend of the prevalence
of MIA and/or HTN indicates that diabetes care in Iran has
improved since the beginning of our study.21 In parallel, the
Tehran Lipid and Glucose Study cohort reported that the use
of antihypertensive, antihyperglycemic, and antihyperlipi-
demic medications was increased substantially over a fol-
low-up period of more than a decade (1999–2011) among
Iranian patients with type 2 diabetes.21 Hence, in the current
follow-up study of 1,337 T2DM patients, after age- and
BMI-adjustment during follow-up, the effects of glucose,
lipid proﬁle, and diabetes duration on having HTN and
MIA separately and the coexistence of both were also esti-
mated using relevant statistical methods.
After adjustment for age and BMI, the risk of having
MIA in women was signiﬁcantly higher than men, similar
to the previous study, disregarding the MIA and HTN
comorbidity in T2DM patients after adjusting for age.22
Although estrogen has protective effects on CVD, our data
might be inﬂuenced by the use of oral contraceptive in the
pre-menopausal women or post-menopausal setting and
hormone replacement therapy after menopause, which
were shown to be associated with an increased prevalence
of MIA.23 However, our ﬁndings indicated that male
patients show a slightly higher risk of having HTN,
when HTN occurred separately or simultaneously with
MIA in age- and BMI-adjusted analysis; the association
of the gender with HTN became insigniﬁcant. This ﬁnding
Adjusted odds ratios of outcomes in each separate condition
Men
A
Men
Duration of diabetes (year)
Duration of diabetes (year)
Uncontrolled plasma glucose
Uncontrolled plasma glucose
Non HDL-cholesterol (mmol/L)
0.3
0.3 0.5 0.70.9 1.11.31.51.7 1.9 2.12.3
0.3 0.5 0.7 0.9 1.1 1.3 1.5 1.7 1.9 2.1 2.3
0.5 0.7 0.9
Odds ratio (95% BCI) of MIA,
when MIA was considered alone
Odds ratio (95% BCI) of HTN,
when HTN was considered alone Odds ratio (95% BCI) of HTN,
when HTN and MIA comorbidity was considered
Odds ratio (95% BCI) of MIA,
when MIA and HTN comorbidity was considered
1.1 1.3 1.5 1.7 0.3 0.5 0.7 0.9 1.1 1.3 1.5 1.7
Men
Duration of diabetes (year)
Uncontrolled plasma glucose
Non HDL-cholesterol (mmol/L)
Men
Duration of diabetes (year)
Uncontrolled plasma glucose
Non HDL-cholesterol (mmol/L)
Non HDL-cholesterol (mmol/L)
Adjusted odds ratios of outcomes in coexistence of HTN and MIA 
C D
B
Figure 3 Effects of risk factors on moderately increased albuminuria and hypertension, when occurred alone or co-occurred with each other in longitudinal assessment. (A)
Effects of risk factors on moderately increased albuminuria, when occurred alone in longitudinal assessment. (B) Effects of risk factors on moderately increased albuminuria,
when co-occurred with hypertension in longitudinal assessment. (C) Effects of risk factors on hypertension, when occurred alone in longitudinal assessment. (D) Effects of
risk factors on hypertension, when co-occurred with moderately increased albuminuria in longitudinal assessment.
Abbreviations: MIA, moderately increased albuminuria; HTN, hypertension.
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is consistent with previous report where the age was
adjusted.11 The higher risk of HTN in male patients with
type 2 diabetes might originate from poor blood pressure
control in this group of patients.3
At the follow-up, T2DM patients with shorter diabetes
duration were at higher risk of having MIA and/or HTN,
where HTN and MIA occurred separately or simulta-
neously after age- and BMI-adjustment. This is in agree-
ment with the previous cross-sectional (without adjustment
for confounders) and longitudinal studies (after base
adjustment for randomized treatments) conducted on the
T2DM patients;24,25 however, the association of the dia-
betes duration with the HTN and MIA comorbidity was
not considered. The longer duration of diabetes was
reported as a strong risk factor for MIA and HTN dis-
orders separately,12 without considering diabetes duration
as a time-dependent variable and the longitudinal analysis.
Although we anticipated higher accuracy in our ﬁndings,
this discrepancy might also originate from divergent dis-
tribution of participants’ diabetes duration or difﬁculties in
recording the duration of diabetes for T2DM patients in
different studies; hyperglycemia usually starts 4–7 years
before the clinical diagnosis of diabetes.26 Moreover, in
our study, the effect of diabetes duration on the risk of
HTN and MIA comorbidity is noticeably stronger than that
of HTN or MIA disorders separately. The results obtained
from the effects of shorter diabetes duration on HTN and/
or MIA suggest that genetic factors might play a role in
the pathogenesis of diabetes complications, including
hypertension, moderately increased albuminuria, and the
coexistence of both conditions at an early stage of the
disease.
At baseline, the age- and BMI-adjusted means of FPG,
2h-PP, and HbA1c were signiﬁcantly higher for T2DM
groups with high blood pressure, MIA, and combined con-
ditions than the normotensive normoalbuminuric T2DM
patients. This was in agreement with parallel results for
glucose proﬁle of T2DM patients with only MIA or with
only HTN in the previous studies.11,12 A systematic review
and a meta-analysis study27 showed that 2 h-PPG and FPG
with HbA1c contributes signiﬁcantly to overall glycemic
control. Furthermore, monitoring of 2 h-PPG will be more
helpful to prevent long-term diabetes complications and
achieve optimal glycemic control than FPG alone in the
absence of HbA1c, especially in developing countries.27 On
the other hand, FPG and 2 h-PPG were recommended as
short-term indicators, in addition to the long-term measure
of HbA1c, to improve the quality of glycemic control.28
Therefore, it was suggested that these three indices should
be considered simultaneously as a useful glycemic control
index for predicting different diabetes complications.
According to this recommendation and to deal with the
observed multicollinearity in glucose proﬁle, we combined
the cut-off points for 2 h-PPG, FPG, and HbA1c variables
to generate a new uncontrolled plasma glucose index, based
on the glycemic control recommendation in non-pregnant
diabetic patients.20
We assessed and compared the glycemic status with
uncontrolled plasma glucose index as a combined index of
the glucose proﬁle and HbA1c among patients with T2DM.
The results obtained from the use of HbA1c instead of
uncontrolled plasma glucose index indicated that the asso-
ciations of the indicator of glycemic control based on
Hba1c with the risk of having HTN and/or MIA weakened
and are insigniﬁcant; however, the associations of other
determinants and confounders with the HTN and MIA
remained signiﬁcant. In parallel, partial raw data of the
current study were used to estimate the incidence and risk
factors of HTN in T2DM patients11 similar to the current
study where the continuous form of HbA1c was included,
no signiﬁcant effect of HbA1c was detected as an indicator
of glycemic control, even after the data were adjusted for
other variables such as cigarette smoking and therapeutic
regimen besides to age and BMI. In the present study,
univariate and bivariate models included uncontrolled
plasma glucose index as a combined index of the glucose
proﬁle, instead of using HbA1c. This model was selected
based on the selection criteria described in methods. In fact,
the uncontrolled plasma glucose index as a combined index
of the glucose proﬁle provided us with a more reliable risk
assessment for HTN, MIA, and the coexistence of both
conditions. Hence, we showed the longitudinal association
of uncontrolled plasma glucose level with HTN, MIA, and
the coexistence of both, based on uncontrolled plasma glu-
cose index as a combined index of the glucose proﬁle, after
age- and BMI-adjustment. This supported the results of a
recent study, showing an increased prevalence of HTN in
T2DM patients with poor glycemic control (HbA1C of
≥6.5%), without adjustment for confounder effects.29
Moreover, the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study, the Action in Diabetes and
Vascular Disease (ADVANCE) study, and the Veterans
Affairs Diabetes Trial (VADT) showed the importance of
glycemic control (HbA1C of <6.5%) on MIA, after therapy
adjustments.30 However, discordance existed between the
research evidence and clinical policy statements about the
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intensity of glycemic control required to reduce micro- and
macro-vascular complications; because population studies
were different in terms of glycemic targets, used anti-hyper-
glycemic agents, comorbidities, and duration of diabetes
mellitus.31,32 T2DM patients with uncontrolled plasma glu-
cose have a different phenotype (who predominately have a
loss of beta cells) to those who have controlled plasma,
such that microvascular damage is experienced.33
Moreover, reduced arterial elasticity, due to long-term expo-
sure of the vascular wall to elevated glucose level, leads to
HTN by increasing peripheral vascular resistance.34
In the current study, uncontrolled plasma glucose
further showed the stronger effect on MIA and HTN
comorbidity than on each disorder separately. The relation-
ship between uncontrolled plasma glucose and the HTN
and MIA comorbidity was not investigated previously.
The Non-HDL-C was used as representative of lipid
proﬁle in the longitudinal assessment. Non HDL cholesterol
provides a single index of apolipoprotein B-containing
lipoproteins.35 This parameter includes very low-density
lipoproteins remnants and potentially atherogenic particles
which are important participants in the development of
CVD disease.36 Our results showed higher age and BMI-
adjusted odds for HTN and MIA in patients with higher
Non-HDL-C, in agreement with the results of previous
studies without considering the coexistence of both and
without adjustment for confounder effects;36,37 however,
the longitudinal association of non-HDL-C with HTN and
MIA comorbidity were not considered in those reports.
It should be noted that the comparison of our ﬁndings
with the previous literature is difﬁcult, especially when it
comes to comparing the effect of risk factors on MIA and
HTN comorbidity with the effect of risk factors on MIA,
and HTN disorders separately, because previous cross-
sectional or longitudinal studies on the associations of
risk factors with HTN and MIA in patients with T2DM
have not tended to focus on HTN and MIA comorbidity.
Study strengths
The strengths of the current study include the use of
samples, consisting of both men and women, using stan-
dard criteria for information on potential determinants of
HTN and MIA. All measurements performed by trained
staff; and the same methods were used to obtain both the
baseline and the follow-up laboratory data. There was no
difference between the potential risk factors of HTN and/
or MIA in participants who were examined once, non-
attendees and those with the follow-up.
Furthermore, we used univariate/bivariate mixed-
effects (with random subject effects) logistic regression.
This statistical model is an appropriate and efﬁcient
method for the analysis of natural history longitudinal
data with dropout. Although it has been common to use
traditional univariate/bivariate ﬁxed-effect logistic regres-
sion for the cross-sectional analysis, and standard univari-
ate/bivariate Cox models for time to incident detection of
the outcomes, these common approaches do not make use
of all the available repeated measures data.18 Bayesian
inference was practically feasible for univariate/bivariate
mixed-effects logistic regression, as well as for model-
based handling missing covariates at random with higher
statistical power than complete case (eliminate cases with
missingness) method.38
Study limitations
Several limitations need to be considered in interpreting
our results. First, we were unable to include several pos-
sible confounding variables that were known as risk fac-
tors for HTN and MIA, such as the type of treatment (diet,
pills, and insulin), smoking behavior, alcohol and salt
consumption (sodium-intake), sleeping disorder, socioeco-
nomic status, and genetic factors. Previous studies11,12 on
Iranian population showed no statistically signiﬁcant asso-
ciation between smoking, the type of treatment and HTN
and MIA, considering other covariates and disregarding
the coexistence of both disorders. The second limitation is
the observational design of our cohort study, which makes
it impossible to assess the exposure that is not made by the
researcher (there is no intervention); it is difﬁcult to assess
the causal-effects of risk factors. Furthermore, the prob-
ability of exposure can be inﬂuenced by extraneous fac-
tors, or confounders, which can also affect the outcome of
the study. Therefore, the causal-effects of the risk factors
are also inﬂuenced by unmeasured confounding factors.
However, our modiﬁcations of the statistical models (spe-
ciﬁcally the random-subject effects in the univariate/
bivariate mixed-effects logistic regressions) allowed us to
somehow overcome this issue in the statistical analysis.
Hence, the random subject effects often interpreted as
latent characteristics that are speciﬁc to the subject repre-
sent the collective impact of factors relevant to the out-
come variables but not included in the model.39
Nonetheless, we do not claim the inclusion of the random
subject effects as ‘adjustment’ for unmeasured confound-
ing variables.
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Conclusion
The high prevalence rates of moderately increased albu-
minuria and its coexistence with hypertension at baseline
have been shown in T2DM patients. The age- and BMI-
adjusted odds of having hypertension, moderately
increased albuminuria, and the coexistence of both condi-
tions were signiﬁcantly increased by increasing non-high-
density lipoprotein cholesterol, shorter diabetes duration,
and uncontrolled plasma glucose. Furthermore, after
adjustment for age and BMI during follow-up visits, dia-
betes duration and uncontrolled plasma glucose showed
signiﬁcant stronger effects on coexisting hypertension and
moderately increased albuminuria than on each separate
condition. Our ﬁndings encourage comprehensive and
motivated bad lipid and glucose proﬁle-loss programmers
at an early stage of the diagnosis of the type 2 diabetes to
prevent hypertension, moderately increased albuminuria,
and particularly the coexistence of both.
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Supplementary materials
Table S2 Baseline characteristics in T2DM patients with or without follow-up
Attendees Non-attendees P-value
Characteristic Mean (SD)
Age (year) 46.34 (8.65) 46.7 (8.66) 0.54
Height (cm) 158.7 (8.54) 159.8 (8.69) 0.08
Weight (kg) 73.04 (11.79) 74.22 (12.56) 0.14
Body mass index (kg/m2) 29.14 (4.61) 29.66 (4.49) 0.09
Fasting plasma glucose (mmol/L) 8.49 (2.45) 8.47 (2.89) 0.93
2-hrs post prandial plasma glucose (mmol/L) 11.85 (3.82) 11.88 (4.14) 0.91
Glycosylated hemoglobin (%) 7.53 (1.76) 7.57 (1.67) 0.71
Triglyceride (mmol/L) 2.05 (1.31) 2.07 (1.15) 0.86
Total-cholesterol (mmol/L) 5.01 (1.01) 4.89 (1.05) 0.09
LDL-cholesterol (mmol/L) 2.93 (0.82) 2.84 (0.86) 0.08
HDL-cholesterol (mmol/L) 1.18 (0.30) 1.15 (0.28) 0.14
Non HDL-cholesterol (mmol/L) 3.84 (0.95) 3.77 (0.99) 0.25
Systolic blood pressure (mmHg) 125 (8.62) 124 (4.92) 0.07
Diastolic blood pressure (mmHg) 79.11 (9.30) 77.98 (8.97) 0.07
24 hrs urine albumin concentrations (mg) 45.74 (10.32) 44.62 (9.23) 0.10
Diabetes duration (Year) 4.55 (4.40) 4.93 (4.59) 0.20
N (%)
Sex
Male 906 (56.6) 166 (10.4) 0.14
Female 431 (26.9) 97 (9.1)
Abbreviations: T2DM, type 2 diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table S1 Correlation between fasting plasma glucose, 2 hrs postprandial plasma glucose, and glycosylated hemoglobin at baseline
FPG (mmol/l) 2-HPPG (mmol/L) HbA1C (%) T-Chol (mmol/L) LDL-Chol (mmol/L)
2-HPPG (mmol/L) r=0.698a
HbA1C (%) r=0.532a r=0.537a
T-Chol (mmol/L) r=0.185a r=0.140a r=0.119a
LDL-Chol(mmol/L) r=0.120a r=0.101a r=0.189a r=0.844a
HDL-Chol (mmol/L) r=- 0.020 r=- 0.011 r=- 0.043 r=- 0.217a r=- 0.130a
Note: aCorrelation is signiﬁcant at the 0.01 level.
Abbreviations: r, pearson correlation coefﬁcients; FPG, fasting plasma glucose; 2-HPPG, 2 hr postprandial plasma glucose; HbA1C, glycosylated hemoglobin; T-Chol, total
cholesterol; HDL-Chol, high-density lipoprotein cholesterol; LDL-Chol, low-density lipoprotein cholesterol.
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